Member Info for LTbeliever

I think the steady stream of RNSs and comments re pipeline etc seems to indicate that the Co seriously wants to put to rest this whole matter of "insufficient cash"; I reckon that by June end, there will a trading update showing exactly how much cash was burned, cash balance etc that should/might assuage these concerns; IMO

I think money is doing the talking - Ozzies are buying for a reason; meeting HAS taken place, if there were disputed terms, disagreements etc about the EPC, an RNS would have been required; therefore, so far, "no news" is good news - IMO.

Isn't he still waiting for a Placing at 0.25p?

Well, ASX was alerted (unlike AIM), meaning that there was a lot more trading there; it looks like the Ozzies are more confident (I wonder why!) that the EPC is getting signed soon.

Just like the 1.30 BUY, 2 days ago.

I have a feeling we are getting 1.30 breached soon. 2p will come too, but maybe only with the RNS?

Another fine day in store?

"Company anticipates further contracts, currently in final negotiation stages, will close before the financial year's end"

"Upon success in this project, there is potential for further downstream development contracts for Aptamer. "

"contracts in the pharmaceutical industry often take significant time to negotiate, frequently include confidentiality restrictions, and sometimes do not meet the materiality threshold for individual announcements."

"We continue to make good progress with our developed Optimer assets, with ongoing discussions around our drug delivery vehicles for the liver. Additionally, our work with Unilever developing Optimers in cosmetics applications continues to advance, alongside our partnership with Neuro-Bio to deliver Optimer binders for use in a rapid diagnostic test for Alzheimer's disease."

Porky, we'd call u the "God of Aptamer", u always seem to post prior to a fresh RNS!

1.06 - 1.11 now

Does anyone make any sense of this? Could it be a partial execution of a bigger BUY order?

Koz of projections of high revenues and licensing agreements; delays led to the SP crashing (from a mkt cap of 80mln to 3mln today); licensing deals will eventually come through so the SP will be rerated - just a matter of when.

And lastly, a quick "reminder" that the Top 5 Pharma Co is still validating, since January, meaning an RNS could be issued at any moment;

"Developed binders for IHC are now undergoing external validation by a top 5 pharma company, with initial results reported as promising and leading to a commercial request for more material. "

BTW, I did correctly say that (a couple of weeks ago) APTA will be issuing at least 2 RNSs monthly.

GLA

NoOneK, I guess the same "post" will appear again, even when the SP is over 1p (next month, IMO); getting there soon.

This is the first RNS since December with a big number mentioned; but, to get to this deal, it's obvious that APTA has been providing some services (for a fee) to this Mexican partner for some time now; also, this is APTA's first announced deal in Latin America, meaning similar deals could be also in the pipeline.

Lastly, such deals further enhance APTA's overall profile in the pharma industry, big boys are racing (as ASTRA announced y'day) to develop new, unique drugs - drugs that need APTA's services to reach the market ahead of competitors. IMO

Https://timsergroup.com/labinvestigacionen.html

Looks like they are in Mexico? Really came out of nowhere, it just shows how many "surprises" like this might be coming our way soon. Remember, Arron promised more announcements by June end.

With sudden jumps like this (20%+), there's bound to be profit taking; however, for the rest of us who know the true potential and that reaching 1p is just 1-2 RNSs away, it just gives us time to buy more at still-low prices.

465k (up to)...that's another 2-month extension of the cash runway.

Released on APTA's LinkedIn and site, y'day:

https://aptamergroup.com/new-paper-small-molecule-drug-monitoring-for-poc-tests/

" The paper represents an innovative approach in the field of drug monitoring. This work involved a significant partnership between the unit of experimental and clinical pharmacology of the National Cancer Institute and Aptamer Group, paving the way for future collaborations, underpinning the relationships between private businesses and public institutions. The use of aptamers to optimise drug dosage looks toward the horizon of personalised and tailored medicine, which is a new frontier in oncology." Lead Author Dr Giuseppe Toffoli

IMO it'd be earlier (EPC Signing); first, "Q2" covers May too; secondly, one of the Broker Notes mentioned "end of May", maybe it was a slip of the tongue? thirdly, all these inside trades "rushing" to beat the RNS issue indicate sooner, rather than later; in any case, the SP didn't double in 4 days just like that; something's up.